Immunogenesis, Inc

ImmunoGenesis is a clinical-stage immuno-oncology biopharmaceutical company re-envisioning the treatment of "cold" tumors, particularly of immune-excluded tumors. Immune-excluded tumors, which account for more than half of all cancers, are characterized by having mechanisms of resistance that suppress the immune response; this subgroup is resistant to current immunotherapies. ImmunoGenesis is creating therapies based on the pathology of these immune-excluded tumors that are rationally designed to overcome immune exclusion and thereby drive an effective immune response. We look at cold, immune-excluded tumors through a new lens, re-envisioning treatment with a deliberate drug development strategy based in cold tumor pathology.